These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30806660)

  • 1. Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study.
    Mollel E; Lekule I; Lynen L; Decroo T
    Int Health; 2019 Nov; 11(6):520-527. PubMed ID: 30806660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
    Mboowa G; Namaganda C; Ssengooba W
    BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study.
    Ullah I; Shah AA; Basit A; Ali M; Khan A; Ullah U; Ihtesham M; Mehreen S; Mughal A; Javaid A
    BMC Infect Dis; 2016 Aug; 16():413. PubMed ID: 27519406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis.
    Tabriz NS; Skak K; Kassayeva LT; Omarkulov BK; Grigolashvili MA
    Microb Drug Resist; 2020 Aug; 26(8):997-1004. PubMed ID: 32181685
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.
    Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H
    Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Xpert MTB/RIF assay on multidrug-resistant tuberculosis treatment outcomes in a health district in South Africa.
    Mahwire TC; Zunza M; Marukutira TC; Naidoo P
    S Afr Med J; 2019 Mar; 109(4):259-263. PubMed ID: 31084692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Xpert
    Beste J; Mutaquiha C; Manhiça I; Jose B; Monivo C; Faria M; Creswell J; Codlin AJ; Michel C; Wagenaar B; Gloyd S; Cowan J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1358-1365. PubMed ID: 30355417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.
    Stagg HR; White PJ; Riekstiņa V; Cīrule A; Šķenders Ģ; Leimane V; Kuksa L; Dravniece G; Brown J; Jackson C
    Emerg Infect Dis; 2016 Mar; 22(3):482-90. PubMed ID: 26889608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.
    Padayatchi N; Naidu N; Yende-Zuma N; OʼDonnell MR; Naidoo K; Augustine S; Zumla A; Loveday M
    J Acquir Immune Defic Syndr; 2016 Sep; 73(1):e1-7. PubMed ID: 27509173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.
    Naidoo P; van Niekerk M; du Toit E; Beyers N; Leon N
    BMC Health Serv Res; 2015 Oct; 15():488. PubMed ID: 26511931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.